BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Isocarboxazid

An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)

227+ PubMed studies analyzed · 10 RCTs · Evidence Score: 46.4

Research Domains

Isocarboxazid has been studied across 13 research domains including 🌤️ Mood & Depression, 🫁 Liver & Detox, 🧠 Focus & Attention, ❤️ Cardiovascular, 🧘 Stress & Anxiety. The primary research focus is 🌤️ Mood & Depression with 44% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Isocarboxazid, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Semustine
2 shared targets
Acrylamide
2 shared targets
Mephenesin
2 shared targets
DEET
2 shared targets
Triacetin
2 shared targets
Diflubenzuron
2 shared targets
Kinetin
2 shared targets
Ethionamide
2 shared targets
Piperazine
2 shared targets
Ascorbic
2 shared targets
Loading evidence profile...

This evidence profile for Isocarboxazid is generated deterministically from 227 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.